TLX Latest Press Releases

-- August 19, 2026 --

Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline Globe Newswire 8:32 PM

-- August 5, 2026 --

Telix to Host R&D Day in New York City on September 22, 2026 Globe Newswire 7:00 AM

-- July 30, 2026 --

Telix H1 2026 Results: Investor Webcast Notification Globe Newswire 6:37 PM

-- July 21, 2026 --

TLX591-Tx ProstACT SELECT Study Published in Cancers Journal Globe Newswire 5:00 PM

-- July 20, 2026 --

Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress Globe Newswire 7:31 PM

Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer Globe Newswire 5:00 PM

-- July 15, 2026 --

First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer Globe Newswire 4:20 PM

-- July 1, 2026 --

FDA Alignment to Advance ProstACT Global Phase 3 Trial Globe Newswire 9:31 PM

-- June 22, 2026 --

Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions Globe Newswire 5:40 PM

-- June 2, 2026 --

Telix and United Imaging Announce Strategic Theranostics Collaboration Globe Newswire 7:00 AM

-- June 1, 2026 --

ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026 Globe Newswire 5:00 PM

-- May 27, 2026 --

Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences Globe Newswire 7:00 AM

-- May 18, 2026 --

IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing Globe Newswire 5:00 PM

-- May 15, 2026 --

Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches Globe Newswire 6:30 AM

-- May 14, 2026 --

EDAP | Focal One and Telix Announce Collaboration Focused on Robotic HIFU and Theranostics in Prostate Cancer Globe Newswire 7:30 AM

-- May 4, 2026 --

New Publication Demonstrates TLX250-Px (Zircaix) Potential in Diagnosing Kidney Cancers Beyond ccRCC Globe Newswire 5:00 PM

-- April 30, 2026 --

TLX101-Px (Pixlumi) MAA Accepted in Europe Globe Newswire 5:43 PM

-- April 29, 2026 --

OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer Globe Newswire 5:00 PM

-- April 27, 2026 --

Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next-Generation Portfolio Approach Globe Newswire 7:27 PM

-- April 21, 2026 --

ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026 Globe Newswire 4:49 PM

-- April 14, 2026 --

Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma Globe Newswire 7:04 PM

-- April 13, 2026 --

Regeneron and Telix Announce Strategic Radiopharma Collaboration Globe Newswire 6:30 AM

Telix and Regeneron Announce Strategic Radiopharma Collaboration Globe Newswire 6:30 AM

-- April 9, 2026 --

FDA Accepts NDA for TLX101-Px (Pixclara) Globe Newswire 6:51 PM

-- April 8, 2026 --

Telix Strengthens Board with Additional Director Appointments Globe Newswire 6:44 PM

-- April 6, 2026 --

Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement Globe Newswire 7:37 PM

-- April 1, 2026 --

Telix Appoints David Gill as Non-Executive Director Globe Newswire 7:53 PM